Knight Therapeutics (KHTRF) announced that Knight’s New Drug Submission for CREXONT has been accepted for review by Health Canada. CREXONT is a novel, oral formulation of carbidopa/levodopa extended-release capsules for the treatment of Parkinson’s disease. The innovative design of CREXONT allows for rapid onset, while leveraging a mucoadhesive polymer for slow LD release, potentially enabling longer LD absorption in the gut. CREXONT is expected to compete in a market size of over $50M in Canada and over $120M in Brazil. In each of these markets, the controlled release portion of the market was $15M, during the twelve-month period ended on September 2024, according to IQVIA. In January 2024, Knight announced that it had entered into an agreement with Amneal Pharmaceuticals (AMRX) for the exclusive rights to seek regulatory approval and commercialize CREXONT in Canada and Latin America. Knight is also working to submit the marketing authorization application in Mexico and Brazil during 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics closes acquisition of Paladin
- Knight Therapeutics Secures US$50 Million Credit Facility to Fuel Growth
- Knight Therapeutics closes $50M revolving credit facility
- Knight Therapeutics Secures Strategic Licensing Agreement with Sumitomo Pharma America, Boosting Market Potential and Investment Appeal